4.9.1Segment

Biotech & Biopharmaceuticals

Research-stage and commercial biotechnology companies developing large molecule therapeutics, cell and gene therapies, and novel biological treatments for disease.

5
Verticals

Overview

Biotech & Biopharmaceuticals covers research-stage and commercial companies developing small-molecule, large-molecule, cell, and gene therapies. It is the innovation engine of healthcare — high-risk, high-reward, R&D-intensive, and the source of the industry's growth — spanning big pharma, mid-cap biopharma, and a vast emerging-biotech ecosystem.

M&A is structural and constant: big pharma faces a wave of patent cliffs (loss of exclusivity on major drugs) and acquires biotech to replenish pipelines, while the GLP-1/obesity franchise (Novo Nordisk, Eli Lilly) has reshaped the sector's growth and valuations. U.S. manufacturing receipts understate the global, IP-driven economics.

Market snapshot

Market size
~$211B
Growth
~1.4%CAGR (2017–22, nominal)
Companies
~2,600
FragmentationConsolidating

U.S. Census Bureau 2022 CBP/Economic Census, NAICS 325411 + 325412 + 325414 (pharmaceutical/biological manufacturing) — U.S. manufacturing receipts; the global, IP-driven market is far larger.

Business model & economics

Revenue model
Patent-protected drug sales and royalties
Recurring revenue
Moderate — on-patent franchises; cliffs reset it
EBITDA margin
High for branded on-patent drugs
Capex intensity
High
  • The innovation engine of healthcare — high-risk, R&D-intensive.
  • Patent cliffs drive constant pipeline-replenishing M&A.
  • GLP-1/obesity franchise reshaped sector growth.

M&A deal context

High deal activity

Who’s acquiring

Big pharma & biopharma strategicsBiotech-acquiring platformsVC- and crossover-backed biotech

What’s driving deals

  • Patent-cliff-driven acquisition of biotech pipelines.
  • GLP-1 and novel-modality competition.
  • Biotech funding cycles and platform deals.

Verticals in this segment

  • 4.9.1.1Biosimilar Developers & Manufacturers

    Companies developing and commercializing FDA-approved biosimilar versions of reference biologic drugs providing lower-cost alternatives in immunology and oncology.

  • 4.9.1.2Cell & Gene Therapy Companies

    Developers of autologous and allogeneic cell therapies, viral vector gene therapies, and gene editing platforms for cancer, genetic disorders, and degenerative diseases.

  • 4.9.1.3mRNA & Nucleic Acid Therapeutics

    Companies developing mRNA, antisense oligonucleotide, siRNA, and other nucleic acid platforms for infectious disease, oncology, rare genetic, and cardiovascular indications.

  • 4.9.1.4Rare Disease & Orphan Drug Developers

    Biotech companies focusing on small patient population diseases with high unmet need, leveraging orphan drug designation for accelerated regulatory pathways and exclusivity.

  • 4.9.1.5Therapeutic Biologics & Monoclonal Antibodies

    Biopharmaceutical companies developing and commercializing monoclonal antibodies, fusion proteins, and biologic therapies for oncology, immunology, and rare diseases.

Find Biotech & Biopharmaceuticals acquisition targets

Search Acquisera’s index for companies classified under Biotech & Biopharmaceuticals (4.9.1) and build a targeted deal pipeline.

Search companies